These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8777181)
1. TCNU in colorectal cancer. How many patients are needed to demonstrate that a drug doesn't work? Wils J Ann Oncol; 1996 Feb; 7(2):211. PubMed ID: 8777181 [No Abstract] [Full Text] [Related]
2. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Smyth JF; Hardcastle JD; Denton G; Alderson D; Grace RH; Mansi JL; Yosef HM; Nordle O; Lauri H; Wählby S Ann Oncol; 1995 Nov; 6(9):948-9. PubMed ID: 8624301 [No Abstract] [Full Text] [Related]
3. TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group. Gundersen S; Dombernowsky P; Cavalli F; Bruntsch U; Renard J; Van Glabbeke M; Pinedo H Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1095-7. PubMed ID: 2759163 [TBL] [Abstract][Full Text] [Related]
4. TCNU: a ray of hope for designer nitrosoureas? Workman P Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1823-8. PubMed ID: 3325292 [No Abstract] [Full Text] [Related]
5. Phase II study of TCNU in advanced breast cancer. Dombernowsky P; Clavel M; Smyth JF; Howell A; van Glabekke M; Renard J; Pinedo HM Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1377-8. PubMed ID: 3181260 [No Abstract] [Full Text] [Related]
6. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group. Smyth JF; Gundersen S; Renard J; Pinedo HM Eur J Cancer Clin Oncol; 1989 Apr; 25(4):755-7. PubMed ID: 2714350 [No Abstract] [Full Text] [Related]
7. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270 [No Abstract] [Full Text] [Related]
8. Phase I study of TCNU, a novel nitrosourea. Smyth JF; Macpherson JS; Warrington PS; Kerr ME; Whelan JM; Cornbleet MA; Leonard RC Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1845-9. PubMed ID: 3436348 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours. Bibby MC; Double JA; Morris CM Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1361-4. PubMed ID: 3181257 [TBL] [Abstract][Full Text] [Related]
10. Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors. Singh G; Graffner HO; Milsom JW; Chaudry IH Dis Colon Rectum; 1993 Apr; 36(4):394-9. PubMed ID: 8458268 [TBL] [Abstract][Full Text] [Related]
11. Activity of a new nitrosourea (TCNU) in human lung cancer xenografts. Fergusson RJ; Anderson LE; Macpherson JS; Robins P; Smyth JF Br J Cancer; 1988 Apr; 57(4):339-42. PubMed ID: 3390369 [TBL] [Abstract][Full Text] [Related]
12. A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung. Vibe-Petersen J; Bach F; Pedersen AG; Smyth J; Hansen HH Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1881-5. PubMed ID: 2561100 [No Abstract] [Full Text] [Related]
13. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU). Vibe-Petersen J; Bork E; Møller H; Hansen HH Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1837-43. PubMed ID: 3436347 [TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines. Roed H; Vindeløv LL; Spang-Thomsen M; Christensen IJ; Hansen HH Cancer Chemother Pharmacol; 1987; 19(4):315-8. PubMed ID: 3036388 [TBL] [Abstract][Full Text] [Related]
15. Experimental cerebral and plasma pharmacokinetic studies of TCNU: implications for brain tumour chemotherapy. Whittle IR; Macpherson JS; Smyth J; Miller JD Br J Neurosurg; 1987; 1(3):365-8. PubMed ID: 3268132 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society. Gatzemeier U; Drings P; Edler L; Fiebig HH; Hinke A; Rieche K; Tessen HW Onkologie; 1990 Jun; 13(3):186-8. PubMed ID: 2168534 [TBL] [Abstract][Full Text] [Related]
17. Effects of tauromustine, a water-soluble nitrosourea compound on NMU-1 murine lung tumor. Pratesi G; Savi G Oncology; 1989; 46(2):132-5. PubMed ID: 2710478 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of tauromustine in disseminated malignant melanoma. Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342 [TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma. Hill SR; Pollard LA; Bibby MC Anticancer Res; 1992; 12(6B):2169-75. PubMed ID: 1295464 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU). Hartley-Asp B; Christensson PI; Gunnarsson K; Gunnarsson PO; Jensen G; Polacek J; Stamvik A Invest New Drugs; 1988 Apr; 6(1):19-30. PubMed ID: 3410663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]